Pivekimab Sunirine vs Tagraxofusp
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD123 · full Acute Myeloid Leukemia pipeline
Pivekimab Sunirine · Decnupaz
Marketed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT04086264 (registry estimate)
No aligned efficacy figure on record for this race.
Tagraxofusp
Marketed by Stemline Therapeutics, Inc.
NCT02113982 · Phase 1/2 · completed
The study was non-randomized, open-label, single-arm, and had no comparator; although complete response is a clinical disease outcome, the main efficacy cohort included only 13 patients. Its reported response rate therefore provides limited controlled evidence for tagraxofusp, and no formal between-treatment primary endpoint comparison was applicable.
Next expected readout: April 2027 · NCT06498973 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Acute Myeloid Leukemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Pivekimab Sunirine | Tagraxofusp |
|---|---|---|
| OS, median | —Trial running · NCT07581002 | —Not reported |
| Complete remission | —Trial running · NCT07581002 | —Not reported |
| Event-free survival, median | —Trial running · NCT07581002 | —Not reported |
| Duration of response, median | —Trial running · NCT07581002 | —Not reported |
OS, median
- Pivekimab Sunirine
- —Trial running · NCT07581002
- Tagraxofusp
- —Not reported
Complete remission
- Pivekimab Sunirine
- —Trial running · NCT07581002
- Tagraxofusp
- —Not reported
Event-free survival, median
- Pivekimab Sunirine
- —Trial running · NCT07581002
- Tagraxofusp
- —Not reported
Duration of response, median
- Pivekimab Sunirine
- —Trial running · NCT07581002
- Tagraxofusp
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Pivekimab Sunirine: no structured comparison results are available for Acute Myeloid Leukemia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Pivekimab Sunirine: 0 of 4 rows · Tagraxofusp: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Tagraxofusp |
|---|---|
| Dropout rate | n/a: no completion milestone16 µg/kg/daya NCT02113982 · Phase 1/2 show 13 more results—16 µg/kg/day NCT02113982 · Phase 1/2 n/a: no completion milestone12 µg/kg/day NCT02113982 · Phase 1/2 —12 µg/kg/day NCT02113982 · Phase 1/2 —12 µg/kg/day NCT02113982 · Phase 1/2 —12 µg/kg/day NCT02113982 · Phase 1/2 n/a: no completion milestone12 µg/kg/day NCT02113982 · Phase 1/2 —12 µg/kg/day NCT02113982 · Phase 1/2 —12 µg/kg/day NCT02113982 · Phase 1/2 n/a: no completion milestone12 µg/kg/day NCT02113982 · Phase 1/2 —12 µg/kg/day NCT02113982 · Phase 1/2 n/a: no completion milestone9 µg/kg/day NCT02113982 · Phase 1/2 n/a: no completion milestone7 µg/kg/day NCT02113982 · Phase 1/2 n/a: no completion milestone7 µg/kg/day NCT02113982 · Phase 1/2 |
| Discontinued due to AEs | 66.7%16 µg/kg/daya NCT02113982 · Phase 1/2 show 13 more results—16 µg/kg/day NCT02113982 · Phase 1/2 0%12 µg/kg/day NCT02113982 · Phase 1/2 —12 µg/kg/day NCT02113982 · Phase 1/2 —12 µg/kg/day NCT02113982 · Phase 1/2 —12 µg/kg/day NCT02113982 · Phase 1/2 0%12 µg/kg/day NCT02113982 · Phase 1/2 —12 µg/kg/day NCT02113982 · Phase 1/2 —12 µg/kg/day NCT02113982 · Phase 1/2 100%12 µg/kg/day NCT02113982 · Phase 1/2 —12 µg/kg/day NCT02113982 · Phase 1/2 0%9 µg/kg/day NCT02113982 · Phase 1/2 33.3%7 µg/kg/day NCT02113982 · Phase 1/2 0%7 µg/kg/day NCT02113982 · Phase 1/2 |
| Serious AEs | 100%16 µg/kg/daya NCT02113982 · Phase 1/2 show 13 more results100%16 µg/kg/day NCT02113982 · Phase 1/2 33.3%12 µg/kg/day NCT02113982 · Phase 1/2 53.8%12 µg/kg/day NCT02113982 · Phase 1/2 30.8%12 µg/kg/day NCT02113982 · Phase 1/2 54.1%12 µg/kg/day NCT02113982 · Phase 1/2 100%12 µg/kg/day NCT02113982 · Phase 1/2 60%12 µg/kg/day NCT02113982 · Phase 1/2 71.4%12 µg/kg/day NCT02113982 · Phase 1/2 100%12 µg/kg/day NCT02113982 · Phase 1/2 55.9%12 µg/kg/day NCT02113982 · Phase 1/2 100%9 µg/kg/day NCT02113982 · Phase 1/2 33.3%7 µg/kg/day NCT02113982 · Phase 1/2 66.7%7 µg/kg/day NCT02113982 · Phase 1/2 |
| Most frequent reported AEs | 16 µg/kg/daya aspartate aminotransferase increased 83.3% anaemia 66.7% hyperglycaemia 66.7% NCT02113982 · Phase 1/2 show 13 more results16 µg/kg/day alanine aminotransferase increased 100% arthralgia 100% aspartate aminotransferase increased 100% NCT02113982 · Phase 1/2 12 µg/kg/day alanine aminotransferase increased 66.7% aspartate aminotransferase increased 66.7% hyperglycaemia 66.7% NCT02113982 · Phase 1/2 12 µg/kg/day alanine aminotransferase increased 61.5% nausea 61.5% aspartate aminotransferase increased 53.8% NCT02113982 · Phase 1/2 12 µg/kg/day alanine aminotransferase increased 76.9% aspartate aminotransferase increased 69.2% fatigue 53.8% NCT02113982 · Phase 1/2 12 µg/kg/day alanine aminotransferase increased 64.9% aspartate aminotransferase increased 59.5% pyrexia 48.6% NCT02113982 · Phase 1/2 12 µg/kg/day alanine aminotransferase increased 100% fatigue 100% hyperglycaemia 100% NCT02113982 · Phase 1/2 12 µg/kg/day oedema peripheral 71.4% alanine aminotransferase increased 42.9% aspartate aminotransferase increased 42.9% NCT02113982 · Phase 1/2 12 µg/kg/day aspartate aminotransferase increased 100% decreased appetite 100% fatigue 100% NCT02113982 · Phase 1/2 12 µg/kg/day aspartate aminotransferase increased 64.7% hypoalbuminaemia 61.8% alanine aminotransferase increased 58.8% NCT02113982 · Phase 1/2 9 µg/kg/day alanine aminotransferase increased 100% fatigue 100% hyperglycaemia 100% NCT02113982 · Phase 1/2 7 µg/kg/day aspartate aminotransferase increased 100% hypoalbuminaemia 100% hypocalcaemia 100% NCT02113982 · Phase 1/2 7 µg/kg/day alanine aminotransferase increased 100% decreased appetite 100% dizziness 100% NCT02113982 · Phase 1/2 |
Notes
- aPopulation comparability has not been reviewed for these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pivekimab Sunirine's landscape · Tagraxofusp's landscape